GlassScriptPhysician profile
Obiageli U Ogbata
NPI 1346552692
$25,550.84
in general payments reported to CMS, 2019-2025
40 companies · $3,036 in 2025
The $3,036 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,175 · 2020: $1,019 · 2021: $2,129 · 2022: $428 · 2023: $2,755 · 2024: $13K · 2025: $3,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Honoraria: $4,002 · Food and Beverage: $3,000 · Travel and Lodging: $1,626 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,159.50 |
| Honoraria | $4,002.00 |
| Food and Beverage | $3,000.20 |
| Travel and Lodging | $1,626.49 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $4,460.05 | 2021-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $4,368.44 | 2021-2025 | Opdivo, Reblozyl |
| Exelixis INC. | $3,196.39 | 2022-2024 | Cabometyx |
| Genentech USA, INC. | $2,749.66 | 2019-2025 | Tecentriq Hybreza |
| Abbvie INC. | $2,419.25 | 2024-2025 | |
| Coherus Oncology, INC. | $2,317.37 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $2,180.24 | 2019-2025 | Tagrisso, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $954.75 | 2020-2025 | |
| Emd Serono, INC. | $469.87 | 2023-2025 | |
| Gilead Sciences, INC. | $427.60 | 2019-2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $232.27 | 2019-2022 | |
| Viiv Healthcare Company | $211.45 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $140.12 | 2024 | |
| Novocure INC. | $125.18 | 2022 | |
| Amgen INC. | $125.00 | 2024 | Krystexxa |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obiageli Ogbata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.